A GCIG randomized phase III study of carboplatin (C) & pegylated liposomal doxorubicin (PLD) (C-D) vs carboplatin (C) & paclitaxel (P) (C-P): CALYPSO results in partially platinum-sensitive ovarian cancer (OC) patients

Authors
Category Primary study
JournalEuropean Journal of Cancer, Supplement
Year 2009
This article has no abstract
Epistemonikos ID: 2f840a084192aeaf58eab431ba828b085c5ea3e0
First added on: May 12, 2020